 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- MM-II / Sun Pharma
Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3316;
MM-II treatment was well tolerated and may provide durable, clinically relevant pain relief. These data support phase 3 studies.
- |||| MM-II / Sun Pharma
Trial completion, Trial primary completion date: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Sep 13, 2022
P2b, N=397, Completed, Sponsor: Sun Pharmaceutical Industries Limited
These data support phase 3 studies. Active, not recruiting --> Completed | Trial primary completion date: Aug 2022 --> May 2022
- || MM-II / Sun Pharma
Trial primary completion date: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Jun 28, 2022
P2b, N=348, Active, not recruiting, Sponsor: Sun Pharmaceutical Industries Limited
Active, not recruiting --> Completed | Trial primary completion date: Aug 2022 --> May 2022 Trial primary completion date: May 2022 --> Aug 2022
- MM-II / Sun Pharma
LARGE MULTILAMELLAR NEUTRAL LIPOSOMES FORM A STABLE LAYER ON ARTICULAR CARTILAGE SURFACE UNDER EX-VIVO PHYSIOLOGICAL COMPRESSION () - Apr 29, 2022 - Abstract #OARSI2022OARSI_628;
The above findings collectively suggest that application of exogenous phospholipids in the form of liposomes can compensate for the lost endogenous SAPLs through the formation of a coating layer on the cartilage surface which in turn provides lubrication to the damaged cartilage. The purpose of the current study was to assess ex-vivo whether physiologically relevant compression load is a key factor in the ability of MM-II liposomes to form this coating layer on the cartilage surface.
- ||| MM-II / Sun Pharma
Enrollment closed, Trial primary completion date: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Mar 11, 2022
P2b, N=348, Active, not recruiting, Sponsor: Sun Pharmaceutical Industries Limited
The purpose of the current study was to assess ex-vivo whether physiologically relevant compression load is a key factor in the ability of MM-II liposomes to form this coating layer on the cartilage surface. Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2022 --> May 2022
- || MM-II / Sun Pharma
Trial completion date, Trial primary completion date: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Feb 2, 2022
P2b, N=348, Recruiting, Sponsor: Sun Pharmaceutical Industries Limited
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2022 --> May 2022 Trial completion date: Nov 2021 --> Aug 2022 | Trial primary completion date: Nov 2021 --> Aug 2022
- MM-II / Sun Pharma
[VIRTUAL] Local and systemic effects following intraarticular injection of MM-II liposomes. Results from two nonclinical toxicity studies in rabbits and dogs () - May 3, 2021 - Abstract #OARSI2021OARSI_319;
Due to their unique characteristics, MM-II liposomes are retained on the cartilage surface, providing long-term lubrication and leading to a reduction in wear of the cartilage. The purpose of these preclinical studies was to evaluate the toxicity of MM-II, when administered via intra-articular (IA) injection into the stifle joint of rabbits and dogs.
- MM-II / Sun Pharma
[VIRTUAL] Intraarticular injection of MM-II liposomes lubricates cartilage in vivo and reduces friction and wear in ex-vivo cartilage models () - May 3, 2021 - Abstract #OARSI2021OARSI_128;
As previously reported in a first-in-human clinical trial, MM-II, when injected intraarticularly, was shown to reduce pain up to 3 months post injection. This study aims to illustrate MM-II’s mechanism of action by studying the localization of the liposomes in the joint following an intraarticular injection into rabbits and using 2 ex-vivo cartilage models for evaluation of MM-II’s lubrication capabilities and its effect on reduction of friction and wear of the cartilage.
- MM-II / Sun Pharma
[VIRTUAL] Intraarticular injection of MM-II, a suspension of empty large liposomes, reduces cartilage degeneration in rat osteoarthritis model () - May 3, 2021 - Abstract #OARSI2021OARSI_15;
Given the lubricating properties, cartilage wear reduction, and pain-lowering effect of MM-II, we hypothesized that IA administration of MM-II may also reduce OA progression. The purpose of the current study was to evaluate the effects of three consecutive IA injections of MM-II with dosing intervals of one per week, on cartilage degeneration in a rat meniscal-tear-induced model of osteoarthritis.
- |||| MM-II / Sun Pharma
Enrollment open: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Feb 16, 2021
P2b, N=312, Recruiting, Sponsor: Sun Pharmaceutical Industries Limited
The purpose of the current study was to evaluate the effects of three consecutive IA injections of MM-II with dosing intervals of one per week, on cartilage degeneration in a rat meniscal-tear-induced model of osteoarthritis. Not yet recruiting --> Recruiting
- |||||| MM-II / Sun Pharma
New P2b trial: Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis (clinicaltrials.gov) - Aug 10, 2020
P2b, N=312, Not yet recruiting, Sponsor: Sun Pharmaceutical Industries Limited
- | MM-II / Sun Pharma
Trial completion: Safety and Efficacy of an Injectable Medical Device to Treat Knee Osteoarthritis (clinicaltrials.gov) - Nov 27, 2012
P1/2, N=40, Completed, Sponsor: Moebius Medical Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed